Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2006

01-11-2006 | Poster Presentation

Poly(ADPribosyl)ation of CTCF: role in breast tumourigenesis

Authors: F Docquier, D Farrar, I Chernukhin, E Klenova

Published in: Breast Cancer Research | Special Issue 2/2006

Login to get access

Excerpt

CTCF is a conserved, ubiquitous and multifunctional 11 Zn finger (ZF) transcription factor with features of a tumour suppressor. CTCF regulates transcription in diverse modes, such as promoter activation and repression, silencing, constitutive and methylation-dependent chromatin insulation. We have previously reported that CTCF can be post-translationally regulated by poly(ADPribosyl)ation and that this modification modulates the insulator function of CTCF [1, 2]. The purpose of the present study is to investigate the role of CTCF poly(ADPribosyl)ation in normal and breast cancer cells. …
Literature
1.
Yu W, Ginjala V, Pant V, Chernukhin I, Whitehead J, Docquier F, Farrar D, Tavoosidana R, Mukhopadhyay R, Kanduri C, et al: Poly(ADPribosyl)ation regulates CTCF dependent chromatin insulation. Nat Genet. 2004, 36: 1105-1110. 10.1038/ng1426.CrossRefPubMed
2.
Klenova E, Ohlsson R: Poly(ADPribosyl)ation and epigenetics: is CTCF PARt of the plot?. Cell Cycle. 2005, 4: 96-101.CrossRefPubMed
Metadata
Title
Poly(ADPribosyl)ation of CTCF: role in breast tumourigenesis
Authors
F Docquier
D Farrar
I Chernukhin
E Klenova
Publication date
01-11-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1562

Other articles of this Special Issue 2/2006

Breast Cancer Research 2/2006 Go to the issue

Oral Presentation

Breast cancer susceptibility after BRCA1/2: finding the genes and potential practical applications

Poster Presentation

New molecular tools and optical technologies to dissect CXCR4 function in breast cancer

Poster Presentation

The NEUREGULIN1gene and breast cancer

Poster Presentation

Role of the Brk tyrosine kinase in breast cancer progression

Oral Presentation

Regulation of recombinational repair by the familial breast cancer susceptibility protein BRCA2

Poster Presentation

High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits